Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555333 · ClinicalTrials.gov registry record · Phase 3
An Open Label Extension Study in Subjects With Fragile X Syndrome
A Phase 3 study, sponsored by Seaside Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 357
- Enrollment target
NCT01555333: Clinical Trial Phase 3 study, sponsored by Seaside Therapeutics.
NCT01555333 is a Phase 3 study that was terminated before completion, run by Seaside Therapeutics. The registered enrollment target is 357 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01555333, a Phase 3 study, was terminated before completion, sponsored by Seaside Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 357 participants
- Enrollment target
Study Summary
This study will enroll subjects who have completed Protocols 209FX301, 209FX302, or are currently participating in Protocol 2202 into a long-term study in which all subjects will receive active drug (arbaclofen).
Interventions
- DRUG arbaclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555333
The ClinicalTrials.gov registry entry for NCT01555333 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arbaclofen is the first listed.
NCT01555333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555333 about?
NCT01555333 is a clinical study titled "An Open Label Extension Study in Subjects With Fragile X Syndrome". This study will enroll subjects who have completed Protocols 209FX301, 209FX302, or are currently participating in Protocol 2202 into a long-term study in which all subjects will receive active drug (arbaclofen).
What is the current status of trial NCT01555333?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 357 participants. The study started on 2011-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01555333?
The interventions under investigation include: arbaclofen (DRUG).
Who is sponsoring clinical trial NCT01555333?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.